newsfilter
← Earnings
Earnings Releases·

REGENXBIO — Third Quarter 2026 Earnings Summary

  • Total revenue declined 69% year-over-year to $9.2 million (vs. $29.7 million in Q3 2025) due to a $21.2 million drop in ZOLGENSMA® royalties following U.S. patent expiration, though ITVISMA® contributed $2.8 million.
  • Net loss narrowed to $40.7 million ($0.62/share) from $61.9 million ($1.20/share) in the prior year, driven by a $38.0 million litigation settlement gain with Sarepta Therapeutics.
  • Cash and marketable securities increased to $251.0 million following a $100.0 million AbbVie milestone and $107.8 million in public offering proceeds; combined with a $39.0 million settlement received in October 2026, operations are funded through late Q4 2027.
  • Key milestones include expected topline data for sura-vec in wet AMD in Q4 2026, a BLA submission for RGX-202 in Q1 2027, and ongoing evaluation of a clinical hold on RGX-121 pending MRI data review.
Company
REGENXBIO INC
Sector
Healthcare
Industry
Biotechnology